ArticleHypertension (Dallas, Tex. : 1979)2008
Sitagliptin augments sympathetic enhancement of the renovascular effects of angiotensin II in genetic hypertension.
Article in Hypertension (Dallas, Tex. : 1979), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Comparative outcomes of heart failure among existent classes of anti-diabetic agents: a network meta-analysis of 171,253 participants from 91 randomized controlled trials.Cardiovascular diabetology · 2019Pooled it
- DPP (Dipeptidyl Peptidase)-4 Inhibition Potentiates the Vasoconstrictor Response to NPY (Neuropeptide Y) in Humans During Renin-Angiotensin-Aldosterone System Inhibition.Hypertension (Dallas, Tex. : 1979) · 2018Trial
- Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans.Hypertension (Dallas, Tex. : 1979) · 2010Trial
- Opiorphin: an endogenous human peptide with intriguing application in diverse range of pathologies.Inflammopharmacology · 2024Review
- DPP-4 Inhibitors as Potential Candidates for Antihypertensive Therapy: Improving Vascular Inflammation and Assisting the Action of Traditional Antihypertensive Drugs.Frontiers in immunology · 2019Review
- The pleiotropic cardiovascular effects of dipeptidyl peptidase-4 inhibitors.British journal of clinical pharmacology · 2018Review
- Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors.Heart failure reviews · 2018Review
- Sitagliptin and risk of heart failure hospitalization in patients with type 2 diabetes on dialysis: A population-based cohort study.Scientific reports · 2016Article
- Sitagliptin protects proliferation of neural progenitor cells in diabetic mice.Metabolic brain disease · 2015Article
- Effect of dipeptidyl peptidase 4 inhibition on arterial blood pressure is context dependent.Hypertension (Dallas, Tex. : 1979) · 2015Article
- Dipeptidyl-peptidase-4 Inhibitors and Heart Failure: Class Effect, Substance-Specific Effect, or Chance Effect?Current treatment options in cardiovascular medicine · 2014Article
- Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system.American journal of physiology. Heart and circulatory physiology · 2014Review
- Sitagliptin ameliorates lipid profile changes and endothelium dysfunction induced by atherogenic diet in rabbits.Naunyn-Schmiedeberg's archives of pharmacology · 2014Article
- The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?Nature reviews. Nephrology · 2014Review
- The nonglycemic actions of dipeptidyl peptidase-4 inhibitors.BioMed research international · 2014 · on this mapReview
- Cardiovascular actions of GLP-1 and incretin-based pharmacotherapy.Current diabetes reports · 2014Review
- Sitagliptin pretreatment in diabetes patients presenting with acute coronary syndrome: results from the Acute Coronary Syndrome Israeli Survey (ACSIS).Cardiovascular diabetology · 2013Article
- Upregulation of CD26 expression in epithelial cells and stromal cells during wound-induced skin tumour formation.Oncogene · 2012Article
- Endogenous adenosine contributes to renal sympathetic neurotransmission via postjunctional A1 receptor-mediated coincident signaling.American journal of physiology. Renal physiology · 2012Article
- Sitagliptin augments angiotensin II-induced renal vasoconstriction in kidneys from rats with metabolic syndrome.Clinical and experimental pharmacology & physiology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Dipeptidyl peptidase IV converts neuropeptide Y(1-36) (Y(1)-receptor agonist released from renal sympathetic nerves) to neuropeptide Y(3-36) (selective Y(2)-receptor agonist). Previous studies suggest that Y(1), but not Y(2), receptors enhance renovascular responses to angiotensin II in kidneys from genetically-susceptible animals. Therefore, we hypothesized that inhibition of dipeptidyl peptidase IV with sitagliptin (antidiabetic drug) would augment the ability of exogenous and endogenous neuropeptide Y(1-36) to enhance renal vascular responses to angiotensin II in kidneys from spontaneously hypertensive rats. This hypothesis was tested using 3 protocols in isolated perfused kidneys. Results from Protocol 1: Exogenous neuropeptide Y(1-36) enhanced renovascular responses to angiotensin II. This effect of neuropeptide Y(1-36) was blocked by BIBP3226 (selective Y(1) receptor antagonist); Exogenous neuropeptide Y(3-36) did not enhance renovascular responses to angiotensin II. Results from Protocol 2: Sitagliptin augmented the ability of exogenous neuropeptide Y(1-36) to enhance renovascular responses to angiotensin II. This effect of sitagliptin was blocked by BIBP3226. Results from Protocol 3: Renal sympathetic nerve stimulation enhanced renovascular responses to angiotensin II; this enhancement was augmented by sitagliptin and abolished by BIBP3226. Neuropeptide Y(1-36) via Y(1) receptors enhances renovascular responses to angiotensin II in kidneys from genetically hypertensive animals. Sitagliptin, by blocking dipeptidyl peptidase IV, prevents metabolism of neuropeptide Y(1-36) and thereby increases the effects of neuropeptide Y(1-36) released from renal sympathetic nerves on Y(1) receptors leading to augmentation of neuropeptide Y(1-36)-induced enhancement of the renovascular effects of angiotensin II. The renal effects of dipeptidyl peptidase IV inhibitors in hypertensive diabetic patients merit a closer examination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.